All eyes are on emergence of second biosimilar

Published: 2013-01-04 07:00:00

Updated: 2013-01-04 07:00:00

Industry officials say that the second biosimilar will be available in the first half of this year as Celltrion won approval to produce the world’s first antibody biosimilar, Resima in July 2012.

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheum...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK